Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe (ASPIRING): an investigator-initiated, multicentre, pragmatic, prospective, randomised, parallel group, open clinical trial of an investigational medicinal product

Research summary

Stroke due to intracerebral haemorrhage (ICH) is a devastating cardiovascular disease that causes 48% of disability-adjusted life years due to stroke. ICH survivors are at high risk of further major adverse cardiovascular or cerebrovascular events (MACE, i.e. hospitalisation due to stroke [ischaemic or ICH], hospitalisation due to myocardial infarction, or cardiovascular death [by ischaemia, bleeding or other vascular causes]). In the REstart or STop Antithrombotics Randomised Trial (RESTART) of 537 people with cardiovascular diseases who survived ICH in the UK, starting antiplatelet drugs after ICH seemed safe and might have reduced MACE risk (Lancet 2019). ASPIRING aims to provide definitive evidence of the superiority of starting antiplatelet drug monotherapy compared with avoiding antiplatelet drugs in addition to standard care to prevent MACE for all ICH survivors.

Principal Investigator

Dr Ivie Gbinigie

Contact us

Email: Rachel.teal@ouh.nhs.uk

IRAS number

1009845